![Justin Chakma](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Justin Chakma
Investor Relations Contact chez
ARS PHARMACEUTICALS, INC.
Fortune : - $ au 31/07/2026
Profil
Justin Chakma is Chief Business Officer at ARS Pharmaceuticals Operations, Inc. since 2019 and Chief Business Officer at ARS Pharmaceuticals, Inc. since 2019.
Former roles include Senior Director-Business Development at Celgene Corp.
from 2015 to 2018, Director & Corporate Development at Receptos LLC in 2015, Director & Strategy at Auspex Pharmaceuticals, Inc. from 2014 to 2015, Associate at Thomas, McNerney & Partners LLC from 2014 to 2015, and VP, Head-Business Development & Strategy at Vedanta Biosciences, Inc. from 2018 to 2019.
Education includes undergraduate studies at the University of Toronto and an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
Postes actifs de Justin Chakma
| Sociétés | Poste | Début |
|---|---|---|
| ARS PHARMACEUTICALS, INC. | Investor Relations Contact | 01/06/2019 |
ARS Subsidiary, Inc.
 ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Develops epinephrine nasal sprays for treatment of severe allergic reactions | Corporate Officer/Principal | 01/06/2019 |
Anciens postes connus de Justin Chakma
| Sociétés | Poste | Fin |
|---|---|---|
Vedanta Biosciences, Inc.
 Vedanta Biosciences, Inc. BiotechnologyHealth Technology Develops microbial therapies that address the human immune system | Corporate Officer/Principal | 01/05/2019 |
| CELGENE | Corporate Officer/Principal | 01/05/2018 |
| RECEPTOS INC | Directeur/Membre du Conseil | 01/11/2015 |
Thomas, McNerney & Partners LLC
 Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Analyste en capital-investissement | 01/06/2015 |
| AUSPEX PHARMACEUTICALS INC | Directeur/Membre du Conseil | 01/06/2015 |
Formation de Justin Chakma
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
52
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapeutics in immune disease | Health Technology |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Finance |
Auspex Pharmaceuticals, Inc.
 Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Develops microbial therapies that address the human immune system | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Develops epinephrine nasal sprays for treatment of severe allergic reactions | Health Technology |
ARS Pharmaceuticals, Inc.
 ARS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
